IP Australia handed a win Thursday to a company challenging a Bayer animal drug patent, but gave Bayer an additional two months to address its concerns about the patent application’s deficiencies.
IP Australia handed a win Thursday to a company challenging a Bayer animal drug patent, but gave Bayer an additional two months to address its concerns about the patent application’s deficiencies.
For information on rights and reprints, contact subscriptions@lawyerly.com.au